^{According to Zhitong Finance App News, Tylomab (688806.SH) issued an announcement. The company received a notice from the State Drug Administration to approve the launch of the Class 1 innovative drug rituvirbizumab injection (trade name: Nedotul®, R&D code: TNM001) independently developed by the company through a priority review and approval procedure.} This product is intended to prevent lower respiratory infections due to RSV in newborns and infants who are about to enter or are born during the first respiratory syncytial virus (RSV) epidemic season.

According to reports, ritavirubimab injection is a recombinant long-acting anti-respiratory syncytial virus (RSV) monoclonal antibody independently developed by the company. By targeting the conservative epitope of the RSV virus pre-fusion conformation (Pre-F) protein, it mediates RSV neutralization and blocks the fusion of the virus with host cells, thereby preventing the virus from entering the cell and exerting a passive immunopreventive effect. As a Class 1 innovative drug completely independently developed by the company, the rituvibizumab injection project has received support from a major national science and technology project. The approval of the drug marks the successful launch of the company's second self-developed innovative all-human monoclonal antibody drug. It is an important milestone in the company's business development, further expanding the company's commercial product matrix, and enhancing the company's market competitiveness.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.